BioCentury
ARTICLE | Financial News

Sept. 27 Financial Quick Takes: Beam hops into IPO queue; plus Amryt, T3, Junshi, Newronika

September 27, 2019 11:32 PM UTC

Beam seeking NASDAQ IPO
Beam Therapeutics filed to raise up to $100 million in an IPO underwritten by J.P. Morgan, Jefferies, Barclays and Wedbush PacGrow. The base editing company has 12 preclinical programs across hematology, oncology, liver, ocular and CNS diseases and expects to begin submitting INDs in 2021. Arch Venture Partners has a 23% stake in the company ahead of the offering; F-Prime Capital Partners owns 19.4% of shares (see “Beam Broadens Base”).

Amryt raises $60M, closes Aegerion buyout
Amryt Pharma plc (LSE:AMYT; Euronext:AMYT) completed its acquisition of the Aegerion Pharmaceuticals Inc. unit of Novelion Therapeutics Inc. (NASDAQ:NVLN) and raised $60 million through the sale of shares to new and existing investors. The combined company will market two drugs: Juxtapid/Lojuxta lomitapide for hypercholesterolemia and Myalept/Myalepta metreleptin to treat lipodystrophy...